RCM
IBB icon

Raleigh Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Raleigh Capital Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.9K Sell
257
-5,790
-96% -$995K 0.02% 279
2026
Q1 		$1.02M Buy
6,047
+4
+0.1% +$684 0.35% 79
2025
Q4 		$1.02M Buy
+6,043
New +$982K 0.37% 75

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Raleigh Capital Management's IBB Position: Q2 2026 in Review

Raleigh Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 96% in Q2 2026, selling an estimated $995K and leaving 257 shares worth $48.9K. The position accounts for 0.02% of the portfolio, ranked #279.

Raleigh Capital Management first reported a position in IBB in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.02M in Q1 2026. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Raleigh Capital Management held 257 shares of iShares Biotechnology ETF worth $48.9K as of Q2 2026.
  • Raleigh Capital Management sold 5,790 iShares Biotechnology ETF shares in Q2 2026, an estimated $995K.
  • iShares Biotechnology ETF made up 0.02% of Raleigh Capital Management's portfolio in Q2 2026, its #279 holding.
  • Raleigh Capital Management first reported a position in iShares Biotechnology ETF in Q4 2025 and has held it in 3 quarters since.
  • Raleigh Capital Management's iShares Biotechnology ETF position peaked at $1.02M in Q1 2026.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.